Hyderabad-based Bharat Biotech gets DCGI nod for phase-3 trials of Covaxin

Covaxin—the country’s first indigenous vaccine— is an inactivated one created from the strain of the infectious SARS-CoV-2 virus. Inactivated vaccines use the killed version of the germ that causes a disease. It helps the immune system mount an antibody response towards the virus. The vaccine was developed along with ICMR- National Institute of Virology

The Hyderabad-based vaccine maker had applied to the DCGI on October 2 seeking permission to conduct Phase 3 clinical trials for its Covid-19 vaccine candidate.

Apart from Bharat Biotech, an indigenously developed vaccine candidate by Zydus Cadila Ltd is also in Phase 2 of human clinical trials.

Pune-based Serum Institute of India, which has partnered with AstraZeneca for manufacturing the Oxford Covid-19 vaccine candidate, is also conducting phase 2 and 3 human clinical trials in the country.

My Express

25 dead in midnight fire at Goa club

Hope Virat Kohli continues doing the same, says Gautam Gambhir after India’s ODI series win against South Africa

Aditya Dhar’s Dhurandhar pushes a bigoted vision, gaslighting the audience into accepting it as entertainment